[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346219-105":59,"doc-detail-346219-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","therapeutic-potential-of-melatonin-in-gastrointestinal-cancers-molecular-mechanisms-preclinical-evidence-and-clinical-implications","Therapeutic Potential of Melatonin in Gastrointestinal Cancers - Molecular Mechanisms, Preclinical Evidence and Clinical Implications","","Gastrointestinal (GI) cancers drive major global morbidity and mortality, prompting demand for new therapeutic strategies. Melatonin (MEL), an indoleamine with pleiotropic actions, is proposed as an adjuvant in oncology through antiproliferative, proapoptotic, and antioxidant effects. This review integrates molecular evidence in GI carcinogenesis, including NF-κB, PI3K/AKT, Wnt/β-catenin modulation, ROS suppression, and circadian gene regulation (CLOCK, BMAL1). Preclinical data show improved chemoradiotherapy response and reduced tumor burden or chemotherapy resistance, while clinical findings suggest risk reduction and mitigation of radiotherapy-induced oral mucositis. Limitations include limited GI trial focus, unstandardized dosing (10–40 mg/day), and molecular heterogeneity, necessitating phase III, chronotherapy optimization, and biomarker-led research.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/therapeutic-potential-of-melatonin-in-gastrointestinal-cancers-molecular-mechanisms-preclinical-evidence-and-clinical-implications/346219/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/therapeutic-potential-of-melatonin-in-gastrointestinal-cancers-molecular-mechanisms-preclinical-evidence-and-clinical-implications/346219.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What therapeutic roles does melatonin have in gastrointestinal cancers?","Question",{"text":112,"@type":113},"Melatonin is discussed as an oncology adjuvant with antiproliferative, proapoptotic, and antioxidant properties, influencing multiple molecular pathways involved in GI carcinogenesis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which molecular pathways and processes does the review highlight for melatonin’s effects?",{"text":117,"@type":113},"Key mechanisms include modulation of NF-κB, PI3K/AKT, and Wnt/β-catenin pathways, suppression of reactive oxygen species, and regulation of circadian rhythm-related genes such as CLOCK and BMAL1.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the main limitations and research needs mentioned for clinical use of melatonin?",{"text":121,"@type":113},"The review notes that fewer than 15% of trials focus on GI cancers, dosing is not standardized (10–40 mg/day), and molecular heterogeneity may limit response; it recommends phase III trials, chronotherapy optimization, and biomarker-driven approaches.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346219,1790905963,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Journal of  \nPineal Research  \nREVIEW   \nTherapeutic Potential of Melatonin in Gastrointestinal Cancers: Molecular Mechanisms, Preclinical Evidence and Clinical Implications  \nMaciej Gonciarz1  | Benita Wiatrak2  | Iga Lombard1 | Łukasz Konecki1 | Joanna Sarbinowska1   \n1Department of Gastroenterology and Internal Medicine, Military Institute of Medicine – National Research Institute, Warsaw, Poland | 2Department of  \nPharmacology, Wroclaw Medical University, Wroclaw, Poland Correspondence: Joanna Sarbinowska ([jsarbinowska@wim.mil.pl](jsarbinowska@wim.mil.pl))  \nReceived: 23 May 2025 | Revised: 22 October 2025 | Accepted: 10 November 2025  \nFunding: The authors received no specific funding for this work.  \nKeywords: antineoplastic agents | antioxidant activity | gastrointestinal cancer | melatonin | therapy  \nABSTRACT  \nGastrointestinal (GI) cancers remain a leading cause of global morbidity and mortality, necessitating novel therapeutic strategies. Melatonin (MEL), an indoleamine with pleiotropic biological activities, has emerged as a promising adjuvant in oncology due to its antiproliferative, proapoptotic, and antioxidant properties. This review synthesizes current evidence on MEL's molecular mechanisms in GI carcinogenesis, including modulation of NF‐κB, PI3K/AKT, and Wnt/β‐catenin pathways, suppression of reactive oxygen species (ROS), and regulation of circadian rhythm‐related genes (e.g., CLOCK, BMAL1). Preclinical studies demonstrate that MEL enhanceschemoradiotherapy efficacy‐reducing tumor volume by 70% in murine colorectal models and decreasing 5‐fluorouracil (5‐FU) resistance via miR‐532‐3p/β‐catenin axis modulation. Clinical trials report a 23%–41% risk reduction in colorectal cancer among shift workers with MEL supplementation and a 53% decrease in radiotherapy‐induced oral mucositis. Despite promising data, limitations persist: fewer than 15% of clinical trials focus on GI cancers, dosing remains unstandardized (10–40mg/day), and molecular heterogeneity (e.g., KRAS mutations in pancreatic cancer) may limit therapeutic responses. Future research must prioritize phase III trials, chronotherapy optimization, and biomarker‐driven approaches, including MT1/MT2 receptor expression and microbiome profiling. Given its low toxicity and putative synergy with immunotherapies, MEL should be regarded as an adjunct under investigation rather than an established option; to date, no GI‐specific phase III randomized trials exist, and clinical signals come primarily from small, heterogeneous cohorts. Dosing is unstandardized and limited by low oral bioavailability (first‐pass) and possible pharmacogenomic variability.  \n1 | Introduction  \n1.1 | Melatonin Biosynthesis: Pineal and Extra‐Pineal Sources  \nMelatonin (N‐acetyl‐5‐methoxytryptamine) is synthesized from tryptophan via serotonin through two key enzymatic steps catalyzed by arylalkylamine N‐acetyltransferase (AANAT) and  \nacetylserotonin O‐methyltransferase (ASMT) [1]. In the pineal gland, AANAT is rhythmically upregulated by nocturnal sympathetic input, generating a pronounced circadian profile of circulating melatonin [1]. Beyond the pineal gland, extra‐pineal synthesis occurs in multiple tissues—including the gastrointestinal tract (enterochromaffin cells), liver, biliary epithelium, pancreas, immune cells, and notably within mitochondria—supporting high local concentrations and paracrine/autocrine actions independent  \n\n| Maciej Gonciarz and Benita Wiatrak contributed equally to this study. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.\u003Cbr>© 2025 The Author(s) . Journal of Pineal Research published by John Wiley & Sons Ltd. |\n\nJournal of Pineal Research, 2025; 77:e70101 1 of 14  \n[https://doi.org/10.1111/jpi.70101](https://d","cbCaistWIkTZX8KH","https://ap.wps.com/l/cbCaistWIkTZX8KH","pdf",969793,14,"English","# Abstract\n# 1 | Introduction\n## 1.1 | Melatonin Biosynthesis: Pineal and Extra-Pineal Sources\n## 1.2 | Melatonin Receptors Beyond the CNS and Their Roles in Tumor Biology\n## 1.3 | Antioxidant Properties","[{\"question\":\"What therapeutic roles does melatonin have in gastrointestinal cancers?\",\"answer\":\"Melatonin is discussed as an oncology adjuvant with antiproliferative, proapoptotic, and antioxidant properties, influencing multiple molecular pathways involved in GI carcinogenesis.\"},{\"question\":\"Which molecular pathways and processes does the review highlight for melatonin’s effects?\",\"answer\":\"Key mechanisms include modulation of NF-κB, PI3K/AKT, and Wnt/β-catenin pathways, suppression of reactive oxygen species, and regulation of circadian rhythm-related genes such as CLOCK and BMAL1.\"},{\"question\":\"What are the main limitations and research needs mentioned for clinical use of melatonin?\",\"answer\":\"The review notes that fewer than 15% of trials focus on GI cancers, dosing is not standardized (10–40 mg/day), and molecular heterogeneity may limit response; it recommends phase III trials, chronotherapy optimization, and biomarker-driven approaches.\"}]","Therapeutic Potential of Melatonin in Gastrointestinal Cancers - Molecular Mechanisms, Preclinical Evidence and Clinical Implications | PDF",1790060525,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/82e39cb11617d7eac9b7cec5a5a9f78f.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb99d6a66d60ae9f116e5173655bf3c0.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b2c48d7d1950dc1da65d33c59a55de96.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eb453926dc36fc703a8f37ed47d46130.webp",980,1287]